home / stock / vtyx / vtyx news


VTYX News and Press, Ventyx Biosciences Inc.

Stock Information

Company Name: Ventyx Biosciences Inc.
Stock Symbol: VTYX
Market: NASDAQ

Menu

VTYX VTYX Quote VTYX Short VTYX News VTYX Articles VTYX Message Board
Get VTYX Alerts

News, Short Squeeze, Breakout and More Instantly...

VTYX - Ventyx Biosciences gets new operations chief

2024-05-16 08:36:00 ET More on Ventyx Biosciences Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares Ventyx rebounds as Oppenheimer upgrades after pipeline updates Seeking Alpha’s Quant Rating ...

VTYX - Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...

VTYX - Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

2024-05-11 13:58:07 ET Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Conference Call May 9, 2024 16:30 ET Company Participants Martin Auster - Chief Financial Officer Raju Mohan - Founder and Chief Executive Officer John Nuss - Chief Scientific Officer C...

VTYX - Ventyx Biosciences GAAP EPS of -$0.62 beats by $0.05

2024-05-09 16:04:01 ET More on Ventyx Biosciences Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares Ventyx rebounds as Oppenheimer upgrades after pipeline updates Seeking Alpha’s Quant Rating ...

VTYX - Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...

VTYX - Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...

VTYX - FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 30, 2024) - Faruqi & Faruqi, LLP, a leading national se...

VTYX - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 29, 2024) - Faruqi & Faruqi, LLP, a leading national se...

VTYX - VTYX FINAL DEADLINE ALERT: Bernstein Liebhard LLP Reminds Ventyx Biosciences, Inc. Investors of Upcoming Deadline

Do you, or did you, own shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)? Did you purchase your shares pursuant and/or traceable to the Company's October 21, 2021 IPO, or between October 21, 2021 and November 6, 2023, inclusive? Did you lose money in your investment in Ventyx Biosciences,...

VTYX - VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Ventyx Biosciences, Inc. Investors of Upcoming Deadline

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX)? Did you purchase your shares pursuant and/or traceable to the Company’s October 21, 2021 IPO, or between October 21, 2021 an...

Next 10